|22 apr 2014||EnterNext congratulates AwoX on its listing on Euronext Paris|
Paris – 22 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs , today celebrated the listing of AwoX, a pure player in connected objects and technologies for the Smart Home, on Euronext’s regulated market in Paris (compartment C).
Founded in 2003 by Alain Molinié and Eric Lavigne, AwoX designs hybrid connected objects and technologies for the Smart Home. Since spring 2013, the company has marketed its own range of connected objects under the AwoX Striim name, focusing on three related areas—lighting, audio and video. Recognised as an innovative company by BpiFrance, AwoX has invented products including the AwoX StriimLIGHT WIFI™, a hybrid light bulb combining sound and light that won the CES Innovations 2014 Design & Engineering Award at the CES trade show in Las Vegas in January 2014. AwoX has also become the key player in wireless connectivity technology under the DLNA (Digital Living Network Alliance) worldwide standard, and is now a life member of the DLNA Board of Directors and the head of the Certification Committee.
AwoX (ticker symbol: AWOX) was listed through the admission to trading of the 2,454,392 ordinary shares making up the company’s equity and 1,109,535 new shares issued under a Global Offering , including full exercise of the extension option and the over-allotment option.
The company’s IPO was targeted at both French and international institutional investors, as well as individual investors. Total demand was €107.3 million, and the offer was oversubscribed 5.7 times.
AwoX Chairman and CEO Alain Molinié added: “We are delighted at institutional and individual investors’ enthusiastic response to AwoX’s listing. We will use funds raised to step up our development and take advantage of the tremendous prospects ahead for connected objects sold over the internet, in particular our Smart Home line. Our aim is to make AwoX a leader in its markets for both technology and sales.”
|17 apr 2014||EnterNext congratulates Genfit on listing on Euronext Paris|
Paris – 17 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs,today celebrated the listing of Genfit in compartment B of Euronext’s regulated market in Paris.
Founded in 1999, with facilities in Lille (France) and Cambridge, Massachusetts (USA), Genfit is dedicated to developing therapeutic treatments and diagnostics in fields with major unmet needs, linked primarily to cardiometabolic disorders, with a particular focus on hepatitis complications including NASH. To meet these major public health concerns, Genfit is developing a portfolio of drug candidates and biomarker candidates in its own R&D programs and in programs conducted jointly with large drug companies.
Genfit (ticker symbol: GNFT) was listed through the admission to trading of the 21,257,671 existing shares making up the company’s equity under the direct listing procedure on Euronext’s regulated market in Paris.
Market capitalisation stood at around €464.5 million on the day of listing.
“We are delighted to accompany Genfit as it enters this new stage in its growth,” said Eric Forest, Chairman and CEO of EnterNext, adding “Listing will raise the company’s profile with investors and give it access to greater liquidity to step up deployment of its strategy.”
Jean-François Mouney, Chairman of Genfit’s Management Board, added “Our transfer to compartment B of Euronext Paris is set to boost Genfit’s visibility as we are integrated into a range of benchmark indices, and will also appeal to investors who prefer Euronext’s regulated market.”
|17 apr 2014||Semapa lists €150 million Bond on Euronext Lisbon|
Initial offer was increased by 50% and orderbook was two times oversubscribed
Lisbon - 17 April 2014 – Euronext, a wholly owned subsidiary of IntercontinentalExchange Group (NYSE: ICE), today announcedthat Semapa listed its EUR 150 million bond issuing on Euronext Lisbon (ISIN PTSEMFOE0003), increasing the initial offering by 50%.
The initial offer of EUR 100m, totally oversubscribed on day one, increased by 50% to EUR 150million, underlining the interest shown by retail investors for this type of product. The interest rate of this issue is six month EURIBOR + 3,25%, with a five year maturity (2014-2019).
This is the 10th Bond issuing listed on Euronext Lisbon this year, making a total of EUR 10 billion listed. Compared with the same period last year, this represents an increase on value of around 50%.
Semapa is a public company, with its head office in Lisbon and its shares were admitted to trading on the regulated Euronext Lisbon market. Semapa is one of Portugal’s largest industrial groups, with a workforce of more than 5,000 and a presence on several continents. More than three quarters of its turnover is generated on foreign markets. Its business activities consist of indirectly managing its holdings in three industrial areas: paper and pulp, through its holding in the Portucel Group; concretes and aggregates, through holdings in the Secil Group; and the environment, through its holding in the ETSA Group.
Bonds are a pivotal mechanism for creating and sustaining enterprises, business investment, and economic growth and are part of the broad spectrum of instruments listed within Euronext markets.
Euronext Lisbon has been advocating strongly for the development of the on-exchange Bond market, for corporate and non-corporate issuers, given the positive direct impact this can have on the economy, as was widely recognized during the financial crisis. Companies, government and investors have been using this market either to finance their projects or to invest their savings, and have benefited from the transparency and broad distribution of Euronext markets as an alternative to bank credit on one side, or deposits on the other.
The successful placement of the “Semapa 2014-2019” bonds and its high rate of demand, also provides an important example which can further incentivise other issuers and consolidate the development of a stronger Bond market in Portugal
|16 apr 2014||Fermentalg lists on Euronext Paris|
Paris – 16 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs,today congratulated Fermentalg, an industrial biotechnology company producing oils and proteins from microalgae, on its listing on Euronext’s regulated market in Paris (compartment C).
Founded in2009 par Pierre Calleja, Fermentalg is an industrial biotechnology company that specialises in producing sustainable oils and proteins derived from the exceptional properties of microalgae. Its patented technology allows it to target a range of fast-growing global markets, from nutrition and animal feed to cosmetics and health, green chemistry and energy. Fermentalg has already signed its first industrial and commercial joint venture for the production of Omega-3 oils rich in EPA and DHA, as well as several other partnerships with leading industrial groups.
Fermentalg (ticker symbol: FALG) was listed through the admission to trading of 7,399,000 existing shares making up the company’s equity and 4,486,091 new shares issued under a Global Offering, including full exercise of the extension option and the over-allotment option.
The company’s IPO was targeted at both French and international institutional investors, as well as individual investors. Total demand amounted to €135 million and the offer was oversubscribed 4.5 times.
The admission and issue price of Fermentalg shares was set at €9.00 per share, at the top end of the indicative price range. The company’s market capitalisation stood at around €107 million. A total of €40.4 million was raised.
“We want to extend a warm welcome to Fermentalg as it lists on Euronext Paris, in an IPO whose resounding success will help raise the company’s profile in France and abroad. And we are delighted at this opportunity to accompany Fermentalg as it moves ahead with new projects, which will benefit from the financing options offered by the Bourse” said Eric Forest, Chairman and CEO of EnterNext.
Pierre Calleja, founder and Chairman & CEO of Fermentalg added, “We are very pleased with the positive response to our company and the clear success of our IPO. And we would like to thank all of the new investors who have joined us, along with the existing shareholders who renewed their trust in us. Thanks to the funds raised, we now have the financial resources to go out and win markets as we scale up for full industrialization and commercialisation of our first products — creating a new champion to seize the ocean of opportunities that awaits.”
|14 apr 2014||TxCell lists on Euronext Paris|
Paris –14 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs, today congratulated TxCell, a French biotechnology company specialising in immunotherapies for the treatment of chronic inflammatory and auto-immune diseases, on its listing. TxCell joined Euronext’s regulated market in Paris (compartment C).
Founded in 2001, TxCell is a biopharmaceutical company based in Sophia Antipolis in southern France. It is developing a new generation of personalised cell-based immunotherapies that use the patient’s own cells to treat severe chronic inflammatory and auto-immune diseases. Through its patented production process, TxCell makes this type of cell therapy economically viable for the first time. Its first candidate drug Ovasave®, now in clinical development, targets patients suffering from Crohn’s disease who are refractory to existing treatments—an estimated 80,000 to 100,000 people a year representing a potential market estimated at around €3 billion. The company’s second candidate drug is Col-Treg, now under development for the treatment of auto-immune uveitis, a rare disease that is one of the main causes of blindness in the industrialised world and whose sufferers currently have a very limited range of therapeutic options.
TxCell (ticker symbol: TXCL) was listed through the admission to trading of 7,860,467 existing shares making up the company’s equity and 2.903.226 new shares issued under a Global Offering.
The admission and issue price of TxCell shares was set at €5.58 per share. The company’s market capitalisation stands at around €63.6 million and a total €16.2 million was raised.
Eric Forest, Chairman and CEO of EnterNext, said: “We welcome TxCell, the seventh life sciences company to join Euronext markets since the beginning of the year. Innovative companies are structures with major growth potential. EnterNext’s aim is to promote the range of financing solutions available on the Bourse and encourage contacts between investors and these companies that are seeking the resources they need to pursue development.”
Damian Marron, TxCell’s Chief Executive Officer, added: “I am delighted with TxCell’s successful listing on Euronext, where the segment dedicated to health-related companies has grown steadily and increased its international reach. I would like to thank our historical shareholders Bpifrance and all of those who have joined our innovative and unique drive to improve the lives of thousands of patients suffering from inflammatory and auto-immune illnesses such as Crohn’s disease.”
|10 apr 2014||SuperSonic Imagine lists on Euronext Paris|
Paris –10 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs, today announced the listing of SuperSonic Imagine, a company specialized in ultrasound medical imaging, on Euronext’s compartment B in Paris.
Founded in 2005 and based in Aix-en-Provence in southern France, SuperSonic Imagine is revolutionising ultrasound technology, a field that had seen no major breakthroughs in over 15 years. The company’s Aixplorer® technology uses software that produces ultrafast scans and displays images with excellent definition, contrast and resolution in real time. It also allowsphysicians to analyse tissue stiffness immediately, thus expediting cancer diagnoses, and features an all-new Doppler mode for vascular illnesses that offers unparalleled speed and sensitivity. After five years of successful sales in radiology, SuperSonic Imagine now has over 800 devices installed in more than 50 countries and is continuing to expand into applications in pediatrics, gynecology, urology and cardiology.
SuperSonic Imagine (ticker symbol: SSI) was listed through the admission to trading of 11,337,376 existing shares making up the company’s equity and the sale of 4,273,504new shares issued under a Global Offering, before any exercise of the over-allotment option.
Total demand amounted to €63.8 million, including €55.7 million through the Global Placement and €8.1 million through the Open Price Public Offering.
The admission and issue price of SuperSonic Imagine shares was set at €11.70 per share. The company’s market capitalisation stood at around € 183 million on the issue date, and a total €50 million was raised.
Eric Forest, Chairman and CEO of EnterNext, commented: “We would like to extend warm congratulations to SuperSonic Imagine on its successful IPO, whose benefits include raising the company’s profile and reinforcing its image in France and on international markets. EnterNext is delighted to accompany this innovative French company in the implementation of its growth strategy.”
Jacques Souquet, SuperSonic Imagine founder and Chairman & CEO, added: “We are delighted with SuperSonic Imagine’s successful IPO on Euronext’s regulated market in Paris. Listing will extend our reach exponentially, both in France and on international markets, as we continue to grow. It represents a milestone in our company’s growth and I would like to thank all of our shareholders—old and new—and our partners and employees for their support and contributions to this success, which is also theirs.”
|10 apr 2014||Quantum Genomics lists on Alternext Paris|
Paris – 10 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs, today congratulated Quantum Genomics, a biopharmaceutical research company developing new therapies for cardiovascular disease, on its transfer from the Free Market to Alternext in Paris following a €3.4 million private placement.
Quantum Genomics is a biopharmaceutical company that develops new therapies for unmet medical needs in the treatment of cardiovascular disease, in particular high blood pressure and heart failure. The company has built a balanced portfolio of candidate drugs using a new therapeutic approach based on Brain Aminopeptidase A Inhibition, developed through over 20 years of research at the Collège de France, INSERM and CNRS.
Quantum Genomics (new ticker symbol: ALGTCL) was listed through the admission to trading on Alternext Paris of 4,747,403 shares making up the company’s equity, including 637,334 newly issued shares resulting from a private placement of around €3.4 million with qualified investors at the unit price of €5.35.
“We congratulate Quantum Genomics on the milestone represented by its successful listing on Alternext, Euronext’s self-regulated market,”said Eric Forest, Chairman and CEO of EnterNext. “This transfer will boost Quantum Genomics’ visibility with larger number of investors. EnterNext will continue to accompany the company as it works to achieve its aims.”
Lionel Ségard, Chairman and CEO of Quantum Genomics, added: “This capital increase is part of our long-term goal of building a shareholder base with investors prepared to participate in Quantum Genomics’ growth and the financing of our research programmes. In the short term, funds raised will enable us to recruit more experts and start clinical phase II testing of our most advanced product for fighting high blood pressure.”
|09 apr 2014||Euronext bouwt Alternext Amsterdam af|
Euronext beurzen verleggen focus naar specifieke behoeftes Nederlandse middelgrote en kleine ondernemingen
Amsterdam - 9 april 2014– Euronext, een volle dochteronderneming van IntercontinentalExchange Group (NYSE: ICE), heeft de intentie Alternext 1 Amsterdam naar aanleiding van een strategische herzieningeind van het jaar of zo spoedig mogelijk daarna te sluiten.
Euronext zal in overleg treden met de uitgevende instellingen van de twee ondernemingen en twee obligaties die momenteel genoteerd zijn aan Alternext Amsterdam om een mogelijke overstap naar Euronext Amsterdam of één van de andere Euronext markten te bespreken.
Sinds de oprichting in 2006 hebben vier ondernemingen een notering gekregen aan Alternext Amsterdam, tegenover meer dan vijftig aan Euronext Amsterdam. Marktpartijen in Amsterdam hebben daarmee een duidelijke voorkeur getoond voor de gereglementeerde markt van Euronext.
Anne Louise Metz, Head of Listings van Euronext Amsterdam, zei: “De Nederlandse financiële gemeenschap heeft haar voorkeur voor noteringen aan de gereglementeerde markt getoond. Daarom hebben we besloten ons te richten op initiatieven voor middelgrote en kleine ondernemingen die meer in lijn zijn met het Nederlandse eco-systeem en beleggings gewoonten.”
Onder de initiatieven voor middelgrote en kleine ondernemingen waar de nadruk op zal liggen in de benadering van Euronext Amsterdam, vallen EnterNext en het recent door de Amsterdamse beurs geïnitieerde NL Ondernemingsfonds. Het NL Ondernemingsfonds is een gezamenlijk marktinitiatief waarbij Nederlandse banken, pensioenfondsen en een vermogensbeheerder de handen ineen geslagen hebben om financiering te bieden voor Nederlandse ondernemingen. Het fonds zal dit jaar haar eerste leningen verstrekken.
Het afgelopen jaar is Euronext dochteronderneming EnterNext gelanceerd die zich richt op het beter gebruik maken van de beurs en het faciliteren van toegang tot de kapitaalmarkt voor middelgrote en kleine ondernemingen. Via EnterNext is Euronext een vertrouwde adviseur voor deze kleinere genoteerde ondernemingen en tevens actief betrokken bij het promoten van de markt bij investeerders en potentiële nieuwe issuers.
1 Alternext is een multilaterale handelsfaciliteit die actief is in België, Frankrijk, Portugal en Nederland. Alternext biedt kleine en middelgrote ondernemingen gemakkelijker toegang tot kapitaalmarkten met minder verplichtingen en een lichter toezicht regime vergeleken met de gereguleerde markten van Euronext.
|08 apr 2014||NN Group N.V. noteert obligatie ter waarde van € 1 miljard aan Euronext Amsterdam|
Amsterdam, Brussel, Lissabon, Parijs - 8 april 2014 - Euronext, een volle dochter van IntercontinentalExchange Group (NYSE: ICE), maakt bekend dat NN Group N.V. vandaag haar succesvolle achtergestelde obligaties ter waarde van € 1 miljard aan Euronext Amsterdam heeft genoteerd (ISIN XS1054522922).
NN Group is een verzekerings‑ en vermogensbeheerbedrijf met een sterke positie in meer dan 18, overwegend Europese landen. Met ruim 12.000 medewerkers biedt het bedrijf pensioenproducten, verzekeringen, vermogensbeheer en bankproducten aan meer dan 15 miljoen klanten. NN omvat onder meer Nationale-Nederlanden, ING Insurance Europe, ING Life Japan en ING Investment Management. NN Group is op dit moment een volle dochteronderneming van ING Group.
De achtergestelde obligaties hebben een looptijd van 30 jaar en zijn aflosbaar na 10 jaar en in elk daaropvolgend kwartaal (onder voorbehoud van goedkeuring door de toezichthouder). De couponrente is vastgesteld op 4,625% per jaar gedurende de eerste 10 jaar en wordt daarna variabel.
“De succesvolle plaatsing van deze achtergestelde obligatie is een belangrijke stap in het realiseren van onze eigen, zelfstandige financieringsstructuur,” zei Lard Friese, vice-voorzitter van NN Group. “We maken goede vorderingen in onze voorbereidingen op een zelfstandige toekomst van onze onderneming. De voorbereidingen voor onze IPO liggen op schema en het is onze intentie om naar de beurs te gaan in 2014, afhankelijk van de marktomstandigheden”.
"Wij zijn verheugd dat NN Group ervoor heeft gekozen de obligatie te noteren aan Euronext Amsterdam," aldus Anne Louise Metz, Hoofd Listings bij Euronext Amsterdam. "Met meer dan 4.500 genoteerde obligaties op onze Europese markten, is Euronext bij uitstek geschikt om in de financieringsbehoeften van issuers te voorzien en hun financieringsdoelstellingen te helpen bereiken. De notering aan Euronext Amsterdam zal leiden tot een grotere zichtbaarheid en liquiditeit van de obligatie en van NN Group."
|08 apr 2014||NIBC lists €500 million bond on Euronext Amsterdam|
Amsterdam, Brussels, Lisbon, Paris – 8 April 2014 – Euronext, a wholly owned subsidiary of IntercontinentalExchange Group (NYSE: ICE), today announced that NIBC Bank
listed its successfully launched EUR 500 million conditional pass through covered bond on Euronext Amsterdam (ISIN XS1054163347).
The issue followed the inaugural and innovative EUR 500 million transaction of October 2013, that gained worldwide recognition and won the IFR Covered Bond of the Year Award.
The conditional pass through covered bond differs from existing bonds, due to the absence of derivatives and inclusion of an orderly wind-down mechanism subject to strict conditions. NIBC’s conditional pass through covered bond program is Dutch law based and backed by a pool of Dutch residential mortgage loans. The program is registered with the Dutch Central Bank and benefits from a favourable regulatory treatment. These features create more stability in ratings and structure. The bonds are expected to be rated AAA by both Fitch and S&P.
“The deal was very well received in the market. The order book was three times oversubscribed with a total of around EUR 1.5 billion, underlining the interest shown by institutional investors from among others Germany, the Netherlands, the United Kingdom, France and the Nordic countries”, said Niek Allon, Associate Director Treasury of NIBC Bank.
“We welcome the listing of this NIBC bond on Euronext Amsterdam,” said Anne Louise Metz, Head of Listing Euronext Amsterdam.”Bonds like this are part of the broad spectrum of instruments we at Euronext are listing in order to support a range of financing sources for our issuers.”
|07 apr 2014||Genomic Vision celebrates successful listing on Euronext Paris|
-IPO raises €23 million-
Paris – 7 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs,today congratulated Genomic Vision,a biotechnology company specialising in molecular diagnostics for genetic diseases, on its successful listing in compartment C of Euronext’s regulated market in Paris.
Genomic Vision is a molecular diagnostics company that develops and markets diagnostic tests and research tools based on analysing individual DNA molecules. To do so, it uses the “molecular combing” technology discovered by Aaron Bensimon, Chairman of the Executive Board and co-founder of Genomic Vision, who was working at the time at the Institut Pasteur’s Unité de Stabilité des Génomes unit in collaboration with a research team from Ecole Normale Supérieure. This cutting-edge technology detects quantitative and qualitative variations in the genome and establishes their role in a given pathology. The company focuses primarily on oncogenetics, the main market for genetic testing.
Genomic Vision (ticker symbol: GV) was listed through a Global Offering. Given very strong demand — a total €93.9 million — the company decided to fully exercise the extension option. The admission and issue price of Genomic Vision shares was set at €15.00, in the middle of the indicative price range.
Altogether 1,533,332 shares were issued, raising a total of €23 million before any exercise of the over-allotment option. Based on a total 4,266,907 shares admitted to trading at €15 per share, Genomic Vision’s market capitalisation stands at €64 million.
The settlement and delivery of the Offering occurred on 4 April 2014. From April 2 through April 4, Genomic Vision shares were traded on an “as-if-and-when-issued” basis.
“We would like to extend a warm welcome to Genomic Vision, and are proud to help raise capital for a growth company specialised in diagnostics for genetic diseases and cancer. Its listing testifies to the very dynamic market for IPOs. Genomic Vision will be able to draw on EnterNext’s advice and services as it makes the most of its presence on the stock market,” said Eric Forest, Chairman and CEO of EnterNext.
Aaron Bensimon, Genomic Vision’s co-founder and CEO, added “We are delighted to join Euronext’s Paris market. We would like to thank all of our shareholders, old and new, who helped us achieve this milestone — and who will now be accompanying us as we roll out our technology in Europe and expand its scope to new pathologies.”
To celebrate the continuous trading in its shares that started today, Aaron Bensimon and his team rang the bell marking the opening of Euronext’s financial markets.
|07 apr 2014||Euronext celebrates the Brussels-Capital Region’s first bond listing on Euronext Brussels|
Brussels – 7 April 2014 – Euronext Group N.V., a wholly owned subsidiary of IntercontinentalExchange Group (NYSE: ICE), announces the successful bond listing by the Brussels-Capital Region on its Brussels market.
The Brussels-Capital Region is one of the three regions of Belgium. It covers the 19 municipalities of Brussels-Capital, and thus forms the core of the urban area of Brussels. The Brussels Region has a total area of 161km² and has 1,200,000 inhabitants.
The two bonds (Medium Term Notes) are admitted to listing on Euronext through a private placement with a total issued amount of € 35,000,000 reaching maturity respectively on the 7th of April 2029 and the 7th of April 2044. The interest rate stand at respectively 2.864% and 3.375%.
“We are pleased to welcome the Brussels-Capital Region’s bond issues on Euronext Brussels”, said Vincent Van Dessel, CEO of Euronext Brussels. “Bonds offer an attractive source of additional funding that are both flexible and efficient, and we are convinced that our bond offering encourages investors to continue investing in the market.The successful placement of the Brussels-Capital Region underscores the vital role capital markets can play in realising the strategic goals of all sorts of players”.
Alain Baetens, Head of Listings of Euronext Brussels: “We are delighted with the Brussels-Capital Region’s strong appreciation of our outstanding Bond Listing and Trading Offer for professionally managed institutions and companies. We look very much forward to a real partnership with the Brussels-Capital Region in bringing them the full benefits of raising funds through the capital markets”.
Guy Vanhengel, Minister of the Government of the Brussels-Capital Region, responsible for Finances, Budget, the Civil Service and Exterior Relations, commented: “This bell ceremony is an exceptional event for the Brussels-Capital Region. It is a recognition of our years of sustained debt management performance, and our excellent financial results. This is a signal that confidence in the Brussels bonds has reached a historic high”.
Today, to celebrate the introduction of the new bonds, Guy Vanhengel, Minister of the Government of the Brussels-Capital Region, responsible for Finances, Budget, the Civil Service and Exterior Relations, rang the bell to open trading on Euronext’s European market. He was accompanied by Vincent Van Dessel , Chairman and CEO of Euronext Brussels, and Alain Baetens, Head of Listings of Euronext Brussels.
|04 apr 2014||Genticel lists on Euronext in Paris and Brussels|
Brussels, Paris –4 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs,today congratulated Genticel, a French biotechnology company and specialist in the development of therapeutic vaccines whose objective is to eliminate the human papillomavirus (HPV) responsible for cervical cancer, on its successful admission to trading on Euronext’s compartment C in Paris and in Brussels.
Based in Paris and Toulouse, Genticel develops therapeutic vaccines against cervical cancer. Its vaccine candidates are aimed at eliminating, at an early stage, cells carrying the human papillomavirus (HPV) responsible for cervical cancer, one of the most common cancers of women worldwide. ProCervix, a “first-in-class” therapeutic vaccine candidate currently in Phase II clinical trials, is designed to eliminate cells infected by type 16 and/or type 18 HPV virus located at the cervix of the uterus before the development of high-grade or cancerous lesions, thus addressing a serious public health problem. Genticel is also developing a second therapeutic vaccine candidate called Multivalent HPV that targets six strains of cancerous HPV.
Genticel (ticker symbol: GTCL) was listed through the admission to trading of existing shares making up the company’s equity and the sale of 4,367,088 newly issued shares, resulting in a capital increase of €34.5 million.
The admission and issue price of Genticel shares was set at €7.90 per share, leading to a market capitalisation of approximately €119.4 million.
“We congratulate Genticel on its dual listing in Paris and Brussels. This IPO will help the company raise its liquidity and visibility with investor communities, both domestic and international,” said Eric Forest, Chairman and CEO of EnterNext. “EnterNext will be advising and assisting Genticel at each stage in its growth and participation in trading, in particular to help it make best use of the range of financing solutions available to it on our markets.”
Benedikt Timmerman, Genticel founder and CEO, said: “We are delighted with investors’ response to our company and with our successful IPO. We would like to extend warm thanks to all the investors that joined us on this occasion, as well as our historic shareholders who renewed their confidence in our company as we reached this important milestone in Genticel’s growth. We are also very pleased with the interest shown by individual investors, particularly in Belgium, and took extra measures to better meet their demand for shares. We now have the financial resources we need to develop our portfolio of candidate therapeutic vaccines, which are designed to give therapeutic options to women carrying the human papillomavirus and thereby reduce the number of cases of cervix carcinoma. In particular, Genticel will continue developing ProCervix, our lead candidate, which has blockbuster potential, with a view to forging a value-creating industrial partnership within the next few years.”
|02 apr 2014||Oncodesign celebrates successful listing on Alternext|
Paris – 2 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs , today extended warm congratulations to Oncodesign, an innovative biotechnology company dedicated to discovering new approaches to cancer and other serious illnesses for which no effective treatments are known, on its successful admission to trading on Alternext in Paris.
Founded by Philippe Genne in Dijon in 1995, Oncodesign is dedicated to accelerating the discovery of new, personalized and effective treatments for patients suffering from cancer. The company’s business model centres on two strategic activities: (1) experimentation through preclinical evaluation of new anticancer therapies on behalf of pharmaceutical and biotech companies, and (2) discovery of new therapeutic molecules, in particular a new generation of kinases, working independently or in partnership with large pharma groups such as Sanofi, Ipsen and UCB. To achieve these goals, Oncodesign draws on cutting-edge solutions that combine science and technology. The company holds a unique position within its market, including solid recognition from over 500 clients around the globe.
Oncodesign (ticker symbol: ALONC) was listed through the admission to trading of 4,390,640 existing shares making up the company’s equity and the sale of 1,749,394 new shares issued under a Global Offering , including full exercise of the extension option. The over-allotment option was also fully exercised, with 77,882 shares sold.
The offering was a resounding success with French and international investors, both institutional and retail. Total demand was €23.5 million, including an €11.6 million Global Placement and an €11.9 million Open Price Public Offering. The IPO raised €12.8 million altogether, with 40% allocated to individual investors.
“We welcome Oncodesign, an innovative international standard-setter in preclinical evaluation and discovery of anticancer treatments, to the market. The success of its IPO with both institutional investors and individuals illustrates the enormous appeal of biotech stocks. Oncodesign will benefit from the assistance of EnterNext’s experts and Euronext’s unique market model for both listing and trading. We are delighted to support the bold and innovative strategy of this company and the many fast-growing businesses listed on Euronext markets,” said Eric Forest, Chairman and CEO of EnterNext.
Oncodesign’s founder, Chairman and CEO Philippe Genne, added: “Our successful listing on Alternext Paris opens a new and critical stage in our growth. It has brought us both the financial resources we need and increased visibility to accelerate our discoveries of new, targeted anticancer therapies that will help treat many patients.”
|02 apr 2014||Euronext vraagt aandacht voor Wereld Autisme Dag 2014|
Amsterdam, Brussel, Lissabon, Parijs – 2 April 2014 – Euronext, een volle dochteronderneming van IntercontinentalExchange Group (NYSE:ICE), vraagt vandaag aandacht voor de zevende, jaarlijkse VN Wereld Autisme Dag met de opening van de markten op alle vier haar locaties (Amsterdam, Brussel, Lissabon, Parijs). De ceremonies werden bijgewoond door diverse wereldwijde organisaties op het gebied van autisme om meer bewustzijn te creëren voor deze aandoening. Volgens de Verenigde Naties zijn er wereldwijd miljoenen mensen met autisme en velen zijn niet gediagnosticeerd, onbegrepen of op zoek naar hulp.
In Amsterdam opende Marjanka Hoogeweg samen met haar autisme-hulphond Creb (spreek uit: Sherp) de beurshandel om begrip te vragen voor mensen met autisme op Wereld Autisme Dag. Zij deed dit in het gezelschap van vertegenwoordigers van de Nederlandse Vereniging voor Autisme, het AutismeFonds en Stichting de Droomboom.
Euronext is als beursorganisatie het centrum van een brede community van bedrijven, financiele intermediairs, adviseurs, investeerders, media en vele anderen met een bijzonder vermogen om te communiceren en een breed publiek te bereiken. Door zichtbaarheid te bieden aan zaken als autisme, gebruikt Euronext een van haar belangrijkste instrumenten - haar communicatie mogelijkheden – als een middel om vorm te geven aan maatschappelijk verantwoord ondernemen.
|31 mar 2014||Euronext announces three new senior appointments|
Amsterdam, Brussels, Lisbon, London and Paris – 31st March 2014 – Euronext, a wholly owned subsidiary of IntercontinentalExchange Group (NYSE: ICE), today announced the appointment of three leaders for its financial derivatives, commodities and cash businesses with effect from 1st April 2014.
Adam Rose will be appointed Head of Financial Derivatives at Euronext. Adam has a strong track record of growing businesses over more than 20 years in the sales and trading of derivatives at Goldman Sachs, and Commerzbank,and in the past seven years as Managing Director at ABN Amro. Adam has extensive experience in both fixed income and equity derivatives and his most recent roles included Head of Sales and Deputy Head of Global Markets at ABN Amro. Adam will be based in Amsterdam.
Olivier Raevel, will be appointed Head of Commodities at Euronext. Olivier is an industry veteran with almost 25 years international experience in global commodities markets. He began his career at Société Générale, where he held various commodities trading roles for over twelve years spent between Paris, London and New York, including as a founding Board member of ICE. Following this, he worked for ABN Amro in London structuring OTC Commodities. He traded energy derivatives during three years at Koch Supply & Trading in Geneva. Olivier will be based in Paris.
Danielle Ballardie will be appointed Head of Cash markets at Euronext. Danielle is one of the UK trading industry’s most high-profile female executives and has been leading the sales and client coverage team in London for Euronext since 2012. Prior to this Danielle spent three years as Director of electronic distribution at Barclays Capital for Europe, the Middle East and Africa, where she helped roll-out its electronic trading business in cash equities and established the bank’s broker crossing network. Before joining Barclays, Danielle spent eight years at the London Stock Exchange in various roles focusing on product development, technology sales and preparing the exchange for the Markets in Financial Instruments Directive. Danielle will be based in London and will act as Deputy to Lee Hodgkinson.
All three appointments will report to Lee Hodgkinson, Head of Markets and Global Sales, Euronext.
“We are delighted to appoint three such outstanding individuals who will help transform our commercial capability as we embrace the exciting challenges of becoming an independent public company,” said Lee Hodgkinson, Head of Markets and Global Sales, Euronext.“This is another step in Euronext’s independence and underlines our commitment to growing the business.”
|31 mar 2014||Euronext Brussels welcomes ABO-Group Environment|
Brussels – 31 March 2014 – Euronext Brussels S.A./N.V., a wholly owned subsidiary of IntercontinentalExchange Group, Inc. (NYSE: ICE), welcomed today ABO-Group on its regulated market.
ABO-Group’s entry on Euronext Brussels’ market occurred through the reverse takeover of Thenergo, a developer, operator and service provider in the context of energy projects. ABO-Group manages a group of companies in Belgium, France and the Netherlands that are specialised in research, studies and advice concerning the soil, energy, waste, environment/water and geotechnics.
The shareholders of ABO Holding NV contribute for 100 % in the shares in the capital of Thenergo at a value of 24,898,000 EUR, and ParticipatieMaatschappij Vlaanderen (PMV) contributes for 1,237,500 EUR from the outstanding balance of its loan that totals 1,495,727 EUR, in the capital of Thenergo. The two contributions take place at an exchange price of 0.01 EUR per share. The shareholders of the ABO Holding company are acquiring more than 94 % of the shares of the new ABO-Group as a result of their contribution.
Vincent Van Dessel, CEO of Euronext Brussels declared: “Euronext welcomes ABO-Group to Euronext Brussels. ABO-Group’s listing raises its visibility with investors in Europe. We congratulate ABO-Group on its listingand look forward to a long-standing partnership with the company and its shareholders”.
Alain Baetens, Head of Listings of Euronext Brussels said: “We are delighted with ABO-Group’s listing on Euronext Brussels and congratulate the company in joining our European markets. We are confident that this listing will benefit ABO-Group in terms of depth of liquidity, international visibility and additional access to new financing sources.”
Frank De Palmenaer, CEO of ABO-Group stated: “We want to be the Belgian engineering and consulting group, who, through its in-house expertise, can undertake the largest projects globally thanks to the drive and relentlessness of its experts and specialists, to whom we offer more than challenging jobs.”
To celebrate the entry of ABO-Group on Euronext Brussels, Frank De Palmenaer, CEO of ABO-Group, rang the bell to open trading on Euronext’s European market. He was accompanied by Vincent Van Dessel, CEO of Euronext Brussels and Alain Baetens, Head of Listings of Euronext Brussels.
|28 mar 2014||CADES opens trading of Euronext’s European market to celebrate successful bond issue|
€5 BILLION BENCHMARK ISSUE STRONGLY ENDORSED BY INTERNATIONAL INVESTORS
Paris – 28 March 2014 – Euronext, a wholly owned subsidiary of IntercontinentalExchange Group (NYSE: ICE),has congratulated CADES (Caisse d’Amortissement de la Dette Sociale) on its successful €5 billion bond issue on 12 February 2014. A leading international issuer, CADES today celebrated that benchmark by ringing the bell that marks the start of trading in Paris.
CADES’mission is to fund and redeem the debt accumulated under France’s general Social Security system. It does this using avery wide range of debt securities which it issues in euros and other currencies in response to demand from international investors. The €5 billion issue by CADES was the largest since its creation in 1996, and was part of its medium and long-term financing programme for 2014.
The issue has a final maturity of 25 May 2019, pays a coupon of 1.125% and has a reoffer price of 99.394%. The transaction was executed with +15.0 basis points over mid-swap, equivalent to a +11.3 basis point spread over OAT benchmark 1% 25 May 2019.
Exceptional demand from investors resulted in an order book of over €7 billion in a record time. Placement was distributed to more than 160 investors from around the world, including 49% in Asia, 22% in Germany and Austria, 7% in France, 5% in the United Kingdom, 4% in the Middle East, 1% in Switzerland and 12% in other European countries.
Central banks and official institutions contributed to more than half of the placement (58%), followed by banks and other financial instutitions (20%), fund managers (18%) and insurance companies (4%).
“Euronext is proud to have worked with CADES on this latest very important bond issue—a benchmark that is an additional positive signal on our markets and confirms their lasting return to pre-crisis levels,”said Marc Lefèvre, Euronext’s Head of European Business Development and Client Coverage. “To finance its requirements, the French State relies primarily on securities issued on financial markets, as in this case with CADES. Euronext offers a wide range of solutions that reflect its key role in financing the economy.”
Patrice Ract Madoux, Chairman of CADES Board of Directors, rang the bell marking the start of trading of Euronext’s European market, accompanied by financial and legal advisers and by the Euronext Paris listing team.
|25 mar 2014||EnterNext congratulates McPhy Energy on successful listing|
Paris –25 March 2014 – EnterNext, the Euronext subsidary designed to promote and grow its market for SMEs, today congratulated McPhy Energy — a specialist in hydrogen-based solutions for energy storage and industrial applications — on its successful listing in compartment C of Euronext’s regulated market in Paris.
McPhy Energy was founded in 2008 at La Motte-Fanjas in southeastern France. Drawing on its exclusive technology for storing hydrogen in solid form, the company designs and manufactures storage and production equipment. Its eco-friendly solutions combine unique safety features, flexibility, energy independence and easy of use. They target users in the mobility, industry and renewable energy sectors, where McPhy Energy has over 1,000 clients.
McPhy Energy (ticker symbol: MCPHY) was listed through the admission to trading of 5,181,091 existing shares making up the company’s equity, of which 3,880,215 were sold under a Global Offering, including exercise in full of the extension clause and the over-allotment option.
The IPO was a resounding success with French and international investors, both institutional and individual. Total demand was €207.3 million, including a €179.8 million Global Placement and a €27.5 million Open Price Public Offering.
The admission and issue price of McPhy Energy shares was set at €8.25 per share i.e. at the high end of the IPO price range. The company’s market capitalisation stands at around €75 million, and a total €32 million was raised altogether.
“We are delighted to enter into a long-term partnership with McPhy Energy,” said Eric Forest, Chairman and CEO of EnterNext.“The company’s IPO will raise its profile and enable it to attract more clients, partners and staff.”
Pascal Mauberger, Chairman of McPhy Energy’s Management Board, said, “We are very happy with the success of our IPO. Thanks to the trust of our former and new shareholders, McPhy Energy now has the resources to accelerate its strategic development plan and play a decisive role in the worldwide energy transition.”
The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.
|25 mar 2014||Euronext Paris and the Algiers Stock Exchange sign memorandum of understanding|
Algiers, Paris – 25 March 2014 – Euronext Paris and Société de la Gestion de la Bourse des Valeurs (SGBV) are pleased to announce the signature of a Memorandum of Understanding (MOU) with a view to enhancing cooperation between their markets.
Under this agreement, Euronext Paris and SGBV will work together to develop their respective stock market ecosystems and make it easier for companies, in particular SMEs, to obtain financing through the stock market.
Main initiatives aimed at encouraging companies to finance growth on markets and helping Algeria’s financial market to expand include: 1) organising events for professionals in finance, including theme-based seminars, training and information sessions in Paris and Algiers, exchange of publications and experience, coordination of joint initiatives ; 2) backing financial research and innovation on topics of common interest including sustainable, environmental and social finance, corporate governance ; and 3) promotion and international development.
Anthony Attia, Chief Executive Officer of Euronext Paris, said, “We are very pleased to enter into this agreement with SGBV, which will enable us to build on our expertise and work with the Algiers Stock Exchange to promote financial markets to companies seeking capital. We look forward to taking part in the Algiers Stock Exchange’s global ambitions via our know-how in financial services.”
Yazid Benmouhoub, CEO of SGBV, added, “The closer ties between our two markets that will result from the signature of this agreement — an historic one for the Algiers Stock Exchange — cannot help but move us closer to achieving the goals we have set. We welcome this new alliance between Euronext Paris and the Algiers Exchange, which is right in line with our efforts to develop financial markets in Algeria.”